Allogene earnings beat fails to halt 6% post-market decline
Investors take profits after 60% February rally, despite extended cash runway and positive EPS surprise
Allogene Therapeutics reported better-than-expected fourth quarter earnings on Thursday, but investors weren't buying the good news, sending shares down 6% in after-hours trading as profit-taking accelerated following a 60% rally in February.
The clinical-stage biotechnology company posted earnings per share of $0.17, beating analyst expectations of a loss of $0.23 by 172.7%. However, with zero revenue and a business model entirely dependent on clinical trial success, investors focused on the binary risks ahead rather than the quarterly beat.
Allogene ended the quarter with $258.3 million in cash and investments, extending its cash runway into the first quarter of 2028. The company develops genetically engineered allogeneic T-cell therapies for cancer treatment, with its most advanced program being the ALPHA3 trial featuring Cema-Cel (cemacabtagene ansegedleucel) for large B-cell lymphoma.
"The earnings beat reflects accounting adjustments rather than underlying operational progress," said one industry analyst who declined to be named. "When you have no revenue, EPS is largely meaningless. What matters is the clinical data, and investors are positioning ahead of make-or-break catalysts."
The stock's 6% decline comes despite overwhelmingly positive analyst sentiment. The consensus rating stands at "Moderate Buy" to "Strong Buy," with an average price target of $7.38—representing nearly 200% upside from the current price of $2.47. Fourteen analysts rate the stock a buy or strong buy, while only one recommends selling.
Two pivotal catalysts loom on the horizon. The company expects to report interim data from the ALPHA3 trial in April 2026, with ALLO-329 autoimmune data scheduled for June 2026. These results will likely determine the company's long-term viability, creating a binary risk profile that explains the volatility around the earnings release.
The February rally that drove shares to a 52-week high of $2.80 was fueled by growing optimism about the ALPHA3 trial, which is evaluating Cema-Cel as a first-line consolidation treatment for large B-cell lymphoma. The stock remains above its 50-day moving average of $1.86 but below its recent peak.
Allogene's allogeneic CAR-T approach differs from autologous therapies like those developed by rivals, as it uses healthy donor cells rather than patient-specific treatments. If successful, this could dramatically reduce manufacturing time and cost, potentially transforming the treatment landscape for blood cancers.
The company's balance sheet remains a strength, with the extended runway providing ample time to generate the clinical data needed to prove its technology. However, with zero revenue and negative profit margins, each quarter represents cash burn rather than earnings generation.
Institutional ownership stands at 66.2%, indicating significant professional investor interest, while insiders hold 16.6% of shares. The stock's beta of 0.50 suggests lower volatility than the broader market, though Thursday's after-hours decline demonstrates that binary clinical events can still trigger sharp moves.
For now, investors appear to be balancing the strong cash position against the uncertainty of upcoming trial results. The April ALPHA3 interim readout will likely be the definitive test for Allogene's valuation, potentially validating the analysts' optimistic price targets or sending shares back toward their 52-week low of $0.86.